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PENILAIAN DAPATAN RAWATAN, KUALITI KEHIDUPAN YANG
BERKAITAN DENGAN KESIHATAN DAN KOS RAWATAN DALAM
KALANGAN PESAKIT PULMONARI TUBERKULOSIS YANG
MEMPUNYAI SMEAR POSITIF
ABSTRAK
Walaupun terapi yang berkesan, namun tuberkulosis (TB) kekal sebagai satu
daripada punca utama morbiditi dan kematian orang dewasa, terutama di negara
membangun. Data yang ada menunjukkan bahawa beban TB semakin meningkat di
Malaysia. Objektif kajian ini adalah untuk menilai pengurusan pesakit PTB positif
smear baru. Ia termasuk pengurusan klinikal, kesihatan berkaitan kualiti kehidupan
(HRQoL), dan petunjuk ekonomi di klinik dada di Hospital Pulau Pinang (HPP),
Malaysia.
Dalam bahagian pertama kajian susulan prospektif ini, semua pesakit PTB
positif smear baru yang berdaftar di klinik dada HPP, di antara Mac 2010 dan
Februari 2011, telah dinilaikan hasil rawatan mereka. Dalam bahagian kedua, pesakit
PTB daripada kohort yang sama diminta melengkapkan soal selidik (SF-36v2)
HRQoL pada mana-mana masa daripada tiga masa pilihan yang diberi sepanjang
rawatan mereka. Selain itu, penjaga keluarga mereka diminta melengkapkan soal
selidik SF-36v2 semasa prosedur mengesan-kontak. Dalam bahagian ketiga, kajian
ekonomi berasaskan insidens telah dijalankan. Jumlah kos rawatan TB dianggarkan
berdasarkan perspektif pembekal dan pesakit.
Kadar kejayaan rawatan TB dalam kajian ini adalah 67.26 %, dan 17.56 %
daripadanya mati semasa rawatan. Sehubungan dengan skor HRQoL dalam kalangan
pesakit PTB positif smear baru, hasil kajian menunjukkan bahawa perbezaan dalam
kalangan skor skala SF-36v2 pada permulaan dan akhir rawatan adalah perbezaan
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minimum klinikal yang penting. Pengulangan analisis ANOVA juga mengesahkan
penambahbaikan yang signifikan dalam HRQoL pada titik masa tersebut. Walau
bagaimanapun, di samping perbezaan tersebut, skor min ringkasan masih di bawah
penanda aras terendah daripada norma populasi am AS. Kajian ini juga mendapati
kesihata mental yang kurang baik dan risiko depresi dalam kalangan penjaga mereka.
Jumlah kos rawatan TB daripada perspektif pembekal dan pesakit adalah MYR
2,218.14. Purata kos pembekal bagi setiap pesakit adalah kira-kira 1.45 kali lebih
tinggi daripada bajet yang diperuntukkan oleh Kementerian Kesihatan bagi rawatan
kes TB. Walau bagaimanapun, perbelanjaan yang ditanggung oleh pesakit dan
penjaga mereka  bagi  rawatan episod semasa TB tidak membebankan mereka.
Purata kos per kontak yang disiasat adalah MYR 21.03. Secara dasarnya, di
Malaysia, kes aktif melibatkan hampir 6 kali ganda dari kes TB berasaskan kadar
insiden TB setiap tahun.
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EVALUATION OF TREATMENT OUTCOME, HEALTH-
RELATED QUALITY OF LIFE AND COST OF TREATMENT IN
SMEAR POSITIVE PULMONARY TUBERCULOSIS PATIENTS
ABSTRACT
Despite the effective therapy, tuberculosis (TB) remains one of the major
causes of adult morbidity and mortality. Available data show that the burden of TB
is slowly increasing in Malaysia. Therefore, this study was conducted with an
objective to evaluate the management of new smear positive pulmonary TB (PTB)
patients. This management included clinical, health-related quality of life (HRQoL)
and economic standpoints at the chest clinic of Hospital Pulau Pinang (HPP),
Malaysia.
In the first part of this prospective follow-up study, all new smear positive PTB
patients who were registered at the chest clinic of HPP, between March 2010 and
February 2011, were evaluated for the outcome of their TB treatment. In the second
part, new smear positive PTB patients and their family caregivers were invited to
self-complete the Short-Form 36 version 2 (SF-36v2) HRQoL questionnaire, while
the third part is an incidence-based economic study. The total cost of TB treatment
was estimated from the perspective of both provider and patient using appropriate
methods.
In this study, there was a 67.26 % TB treatment success rate, whereby 17.56 %
patients died during their treatment. With regard to HRQoL scores on the part of new
smear positive PTB patients, the study’s findings showed that the differences
between the SF-36v2 scale scores at the start and end of the treatment were clinically
significant (minimal clinically important difference). One-way repeated measures
ANOVA analysis also confirmed, at these time points, significant improvement in
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HRQoL scores. However, despite these improvements, the mean summary scores
were still less than the lowest benchmark of the United States general population
norms. Similarly, the study’s findings showed the existence of poor mental health
and risk of depression among the caregivers of TB patients.
The average cost of TB treatment, from the perspective of both provider and
patient, was MYR 2,218.14. The average provider cost was approximately 1.45
times that of the budget allocated by the Ministry of Health for treating a case of TB.
The expenses borne by the patients and their families, on the treatment of current
episode of TB, were not catastrophic for them. The average cost of contact tracing
procedure was MYR 21.03. Active case finding process yielded approximately 6
times more TB cases than the annual incidence rate of TB in Malaysia.
1CHAPTER 1
INTRODUCTION
1.1 Tuberculosis
Tuberculosis (TB) is an infectious disease caused by the bacillus
Mycobacterium tuberculosis (M. tb) (World Health Organization, 2013). The
bacillus, which is an obligate intracellular pathogen, can infect almost any part of
human body. However, lungs are the predominant site of infection. The infection is
transmitted from one person to another when an individual with active pulmonary
tuberculosis (PTB) sneezes or coughs the bacilli in the form of aerosolized droplets.
Because the respiratory droplets remain suspended in the air for many hours, the
chances of transmission are higher in crowded and poorly ventilated areas (Beggs,
Noakes, Sleigh, Fletcher, and Siddiqi, 2003; Canadian Tuberculosis Committee,
2007; Guo, 2010; Lawn & Zumla, 2011).
When healthy individuals are infected with M. tb, 5–10 % of them are likely to
get the disease (World Health Organization, 2002). The remaining 90 % of the
infected people live with latent TB infection (LTBI), and never develop disease. The
risk of developing active TB is dependent on various factors like number of inhaled
bacilli, older age, close contact with an active TB patient, cigarette smoking, alcohol
use and the presence of any underlying immune-compromised condition (e.g., the
use of immunosuppressant drugs, drug abuse and co-infection with human
immunodeficiency virus) (Guo, 2010; Lawn & Zumla, 2011).
2The signs and symptoms of TB include those associated with the disease site
and non-specific constitutional symptoms like loss of weight (LOW), loss of appetite
(LOA), fever, fatigue and night sweats. With regard to PTB, the patients usually
present with the history of chest symptoms such as cough (productive or non-
productive), chest pain and hemoptysis (Lawn & Zumla, 2011; Ministry of Health,
2012b).
The diagnosis of TB is made through the medical history of the patient,
physical examination, imaging and bacteriological results. Usually, it is difficult to
diagnose extrapulmonary tuberculosis (EPTB) in that it requires specimen (i.e.,
tissues or fluids) to be collected from the disease site for cytology/histopathological
examination, measurement of adenosine deaminase (ADA) levels, M. tb cultures and
real time polymerase chain reaction (PCR). Advanced imaging techniques such as
computerized tomography (CT), magnetic resonance imaging (MRI) and
ultrasonography (US) are also used for the diagnosis of EPTB.
The detection of acid-fast bacilli (AFB) on smear and cultures are the most
commonly employed diagnostic methods for drug-sensitive PTB. According to the
recommendations of World Health Organization (WHO), a suspected PTB patient
should submit at least two early morning sputum samples for smear examination in a
quality-assured laboratory. Similarly, chest radiography is also the primary modality
in the diagnosis of PTB.
Automated liquid culture and sensitivity systems, and nucleic acid
amplification tests (NAATs) are the most promising advances in the diagnosis of
TB. These tests have become available for not only recovering M. tb from the
clinical specimens but also generating drug sensitivity testing (DST) data with a
3shorter turnaround time than the agar proportion method (Bemer, Palicova, Rüsch-
Gerdes, Drugeon, and Pfyffer, 2002; Lawn & Zumla, 2011; World Health
Organization, 2009). Similarly, interferon-gamma release assays (IGRAs) are the
most recent advancements in the diagnosis of LTBI. However, tuberculosis skin test
(TST), which is a relatively less reliable method, is still used to identify the people
whose immune system has been previously exposed to M. tb (Lawn & Zumla, 2011).
Bacille Calmette–Guérin (BCG) is a widely used vaccine against TB.
Numerous clinical trials have shown that the protective efficacy of BCG vaccine
ranges from 80 % to a negative effect. The variation in the findings of these trials
might be a consequence of differences in study design and geographical location.
Nevertheless, the vaccine seems to have a protective effect against disseminated
forms of TB disease in children (Arbeláez, Nelson, and Muñoz, 2000; World Health
Organization, 2013a).
1.1.1 Epidemiology of Tuberculosis
TB is a major public health tragedy. In 2012, an estimated 8.6 million people
developed TB (World Health Organization, 2013). With an estimated 1.3 million
deaths every year it ranks second major cause of adult mortality from an infectious
disease worldwide, after human immunodeficiency virus (HIV) (World Health
Organization, 2013). With the emergence of acquired immunodeficiency syndrome
(AIDS) epidemic, there was observed an increase in the global burden of TB because
these infections are closely linked, and synergize one another. The emergence of
multidrug-resistant TB (MDR-TB; M. tb strains resistant to at least isoniazid and
rifampicin) and extensively drug-resistant TB (XDR-TB; M. tb strains resistant to
isoniazid, rifampicin and any member of quinolone family, and at least one of the
4injectable drugs such as kanamycin, capreomycin or amikacin) are further
contributions that have fueled the epidemic. It has been estimated that between 2000
and 2020, approximately one billion people will be infected with M. tb, 200 billion
infected people will develop active disease and 35 million will die from TB if
prevention and control plans are not further developed and executed (Guo, 2010;
World Health Organization, 2012).
It is well known that TB is a disease of people with low socioeconomic
status, and those with inadequate access to health care facilities. According to a
recent report, TB is most common in developing countries (World Health
Organization, 2012). In 2011, approximately 60 % of TB cases occurred in Asia,
followed by 26 % of cases in Africa. Thereafter, smaller proportions of cases
occurred in the Eastern Mediterranean Region (7.70 %), the European Region (4.30
%) and the Region of the Americas (3 %). The 22 high burden countries alone share
82 % of incident cases globally. In 2011, five countries with the largest incidence of
cases were India, China, South Africa, Indonesia and Pakistan (in decreasing order).
India and China alone share 26 % and 12 % of worldwide TB cases, respectively
(World Health Organization, 2012).
Malaysia is situated in the Western Pacific region of WHO, and is ranked as an
intermediate burden TB country (World Health Organization, 2012). In Malaysia, for
the last 3 years, the incidence rate of TB has been 80‒82 cases per 100,000
population (World Health Organization, 2013). However, the absolute number of
new cases has increased from 15,057 in 2000, up to 21,851 in 2012 (World Health
Organization, 2013). In 2009, there were 1,582 TB-related deaths, up from 942 in
2000 (United Nations, 2011). Similarly, from 1990 to 2011, the number of cases
5with TB-HIV co-infection increased from six to 1,630 (Ministry of Health, 2012a).
All of these facts and figures illustrate slowly increasing burden of TB in Malaysia.
1.1.2 Treatment of Tuberculosis
The fundamental objectives of TB treatment are (World Health Organization,
2012):
 To successfully treat the disease.
 To restore quality of life and productivity.
 To stop the transmission of M. tb.
 To prevent the chances of relapse.
 To prevent the development and transmission of MDR-TB.
However, from the patient and provider perspectives, this task is somewhat
challenging because it requires a complex treatment regimen for at least 6 months
(Bass et al., 1994). To counter these treatment challenges, WHO introduced, in mid-
1990s, a directly observed therapy (DOT). The five core components of DOT
include:
i. Political commitment with adequate financing.
ii. Early diagnosis through quality assured sputum smear microscopy.
iii. An uninterrupted supply of first-line anti-TB drugs.
iv. Provision of the standardized treatment regimen under supervision.
v. Evaluation of the case detection and outcome of treatment.
Within a decade, almost all countries adopted the DOT strategy, and there was
a substantial progress towards global targets set for 2005 (i.e., detection of at least 70
6% of estimated smear positive PTB cases and a successful outcome of 85 % of these
cases). For the first time, the global target of 85 % treatment success rate was
achieved in 2005 (World Health Organization, 2012).
In 2006, WHO launched the Stop TB Strategy to strengthen TB care and
control. This strategy was linked to the new global targets which were set for 2015 as
a part of the Millennium Development Goals (MDGs). According to these targets,
there should have a decreasing trend in the incidence of TB by 2015, and in
comparison to the levels in 1990 there needs to be a 50 % reduction in the prevalence
and mortality rates associated with TB. These targets were endorsed and described in
the Global Plan developed by the Stop TB Partnership. The latest Global Plan to
Stop TB covers the period from 2011 to 2015, and states that the treatment success
rate (in annual cohort) should not be less than 90 % (World Health Organization,
2012).
In 1961, Malaysian government launched its National Tuberculosis Program
(NTP) (Iyawoo, 2004). The country and state TB control programs are headed by the
Director General of Health and the state Director of Health, respectively. The
organizational structures for the national and state TB control programs are given in
Figure 1.1 and Figure 1.2, respectively.
7Figure 1.1. Organization chart of the tuberculosis program in Malaysia. Adapted
from “tuberculosis in Malaysia: problems and prospect of treatment and control”
by Kuppusamy Iyawoo, 2004, Tuberculosis, 84, 4-7. Copyright [2004] by
Elsevier. Reproduced with permissions (License number: 3150600709370).
Figure 1.2. Organization chart of the tuberculosis program in each state of
Malaysia. Adapted from “tuberculosis in Malaysia: problems and prospect of
treatment and control” by Kuppusamy Iyawoo, 2004, Tuberculosis, 84, 4-7.
Copyright [2004] by Elsevier. Reproduced with permissions (License number:
3150600709370).
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81.1.2.1 Standard Anti-Tuberculosis Drugs
Table 1.1 provides details of essential first-line anti-TB drugs including their
recommended doses and common side effects. As this study includes only new
smear positive PTB patients, the detail of treatment regimen is based on this sub-
group of patients.
Table 1.1
Recommended Doses of First-Line Anti-Tuberculosis Drugs in Adults, and their Side
Effects
Drug
Recommended dose
Common side
effects
Daily Three times per week
Dose and
range (mg/kg
body weight)
Maximum
(mg)
Dose and
range (mg/kg
body weight)
Maximum
(mg)
Isoniazid* 5 (4‒6) 300 10 (8‒12) 900 Skin rashes,
jaundice, hepatitis,
anorexia, nausea,
abdominal pain,
burning sensation
and numbness or
tingling sensation
in the hands or feet
Rifampicin 10 (8‒12) 600 10 (8‒12) 600 Skin rashes, shock,
purpura, jaundice,
hepatitis, anorexia,
nausea, abdominal
pain, orange or red
urine, acute renal
failure and flu
syndrome
Pyrazinamide 25 (20‒30) 2000 35 (30‒40) 3000 Skin rashes,
jaundice, hepatitis,
anorexia, nausea,
abdominal and
joint pain
Ethambutol 15 (15‒20) 1600 30 (25‒35) 2400 Visual impairment
Streptomycin 15 (12‒18)
10 for > 60
years old
1000
750 for >
60 years
old
15 (12‒18)
10 for > 60
years old
1500
1000 for >
60 years
old
Skin rashes,
deafness, dizziness
and decreased
urine output
*Pyridoxine should be added when isoniazid is prescribed. Notes. Modified from Management of
Tuberculosis: Clinical Practice Guidelines (3rd ed.), Ministry of Health Malaysia, 2012, Putrajaya,
Malaysia: Malaysia Health Technology Assessment Section (MaHTAS). Copyright [2012] Malaysia
Health Technology Assessment Section. Reproduced with permission.
9Fluoroquinolones (i.e., ofloxacin, levofloxacin, moxifloxacin) are the most
common second-line anti-TB drugs used in non-hepatotoxic anti-TB regimens. Table
1.2 provides details of recommended doses of fluoroquinolones, and their common
side effects.
Table 1.2
Recommended Doses of Fluoroquinolones in Adults, and their Side Effects
Drug
Daily dose
(mg/kg body
weight
Maximum
dose (mg) Frequency Common side effects
Ofloxacin 15‒20 1000 Twice daily (common
dose is 400 mg two
times in a day)
Gastrointestinal
intolerance, headache,
malaise, insomnia,
restlessness, dizziness,
allergic reactions,
diarrhea and
photosensitivity
Levofloxacin 7.5‒10 1000 Daily (common dose
is 750 mg in a day)
Moxifloxacin 7.5‒10 400 Daily (400 mg)
Notes. Modified from Management of Tuberculosis: Clinical Practice Guidelines (3rd ed.), Ministry of
Health Malaysia, 2012, Putrajaya, Malaysia: Malaysia Health Technology Assessment Section
(MaHTAS). Copyright [2012] Malaysia Health Technology Assessment Section. Reproduced with
permission.
Isoniazid, pyrazinamide and rifampicin are the most common anti-TB drugs
known to cause hepatic damage. The management of liver damage caused by anti-
TB drugs depends on the severity of damage, severity of TB, capacity of health care
unit to treat side effects and the phase of TB treatment.
If it is confirmed that hepatitis is caused by first-line anti-TB drugs, the
treatment should be immediately stopped. Clinicians should wait until liver function
tests are normalized and clinical symptoms (e.g., nausea and abdominal pain) are
resolved. Then, first-line anti-TB drugs should be reintroduced one at a time. It is
recommended to start with rifampicin because it is less likely to cause hepatotoxicity
than isoniazid and pyrazinamide, and is the most effective agent (Centers for Disease
Control and Prevention, 2003; Saukkonen et al., 2006). Isoniazid should be
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introduced (within a week) after the rifampicin. If the patient is able to tolerate both
rifampicin and isoniazid, the introduction of pyrazinamide should be avoided.
1.1.2.2 Standardized Treatment Regimens
The treatment of TB is divided into two phases: the intensive phase (IP)
and continuation phase (CP). In relation to the standard treatment, WHO strongly
recommends 2HRZE/4HR regimen (isoniazid (H), rifampicin (R), pyrazinamide (Z)
and ethambutol (E) for 2 months during the IP / isoniazid (H), rifampicin (R) for 4
months during the CP) in newly diagnosed smear positive PTB patients. However,
provided that the patient is neither HIV positive nor living in HIV prevalent settings,
an alternate therapy is 3 times weekly dosing throughout the therapy
[2(HRZE)3/4(HR)3] (3 times weekly isoniazid (H), rifampicin (R), pyrazinamide (Z)
and ethambutol (E) for 2 months during the IP / 3 times weekly isoniazid (H),
rifampicin (R) for 4 months during the CP). Similarly, during the CP of the
treatment, patients with isoniazid-resistant TB may be prescribed 4HRE therapy
(Ministry of Health, 2012b; World Health Organization, 2009).
With regard to co-management of HIV and active TB disease, WHO now
recommends the use of 2HRZE/4HR therapy. Three times weekly dose during the IP
is no longer recommended owing to 2‒3 times higher chances of relapse and
treatment failure in HIV co-infected patients. However, an acceptable alternative is 3
times weekly therapy during the CP. Nevertheless, co-trimoxazole should be started
in HIV positive TB patients as a preventive measure against Pneumocystis jirovecii,
the malarial parasite and a range of bacterial infections (World Health Organization,
2009).
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Compliance to the standard anti-TB regimen is critical for the success of
treatment. To enhance the compliance among TB patients, WHO has recommended
using fixed-dose combinations (FDCs) of anti-TB drugs. Studies have shown that
compared with separate-drug regimens, FDCs reduce the risk of non-compliance by
17 % (Bangalore, Kamalakkannan, Parkar, and Messerli, 2007). In addition, FDCs
are thought to reduce the acquisition of drug resistance because patients cannot be
selective in their choice of drugs to ingest. Similarly, prescription errors are less
likely to happen with FDCs because the dosage recommendations are uncomplicated
and adjustment in the dosage, according to patient body weight, is easier (World
Health Organization, 2009).
The two FDCs, available in Ministry of Health (MOH) Malaysia Drug
Formulary, are (Ministry of Health, 2012b):
i. Four-drug combination tablet: isoniazid 75mg, rifampicin 150mg,
ethambutol 275mg and pyrazinamide 400 mg.
ii. Three-drug combination tablet: isoniazid 75mg, rifampicin 150mg and
pyrazinamide 400 mg.
These FDCs are prescribed during the IP of the treatment. The recommended
doses for the available combinations are as follows:
 30‒37 kg body weight: 2 tablets daily.
 38‒54 kg body weight: 3 tablets daily.
 55‒70 kg body weight: 4 tablets daily.
 More than 70 kg body weight: 5 tablets daily.
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1.1.2.3 Monitoring Drug Treatment
Response to TB treatment in a new smear positive PTB patient is usually
monitored by sputum smear examination at the end of the IP of the treatment.
Additional sputum smear microscopy is required at the third month if sputum smear
was positive at the end of second month of the treatment. However, despite the
sputum positivity at the end of second month, it is recommended not to extend the IP
of the treatment. Smear positivity at the end of fifth or sixth month of the treatment
is considered as treatment failure. In such a case, patients should be further tested
using sputum culture and DST, and their treatment should be restarted.
It is notable that the fourth edition of TB treatment guidelines recommends a
limited use of culture and DST for the new patients presumed to have drug-
susceptive TB. However, if the patient belongs to a setting with high prevalence of
isoniazid resistance, or if the patient has established active TB after known contact
with a patient having drug-resistant TB, culture and DST should be performed at the
start of the treatment. Another important recommendation of WHO is mandatory
screening of all TB patients for HIV co-infection (World Health Organization,
2009).
1.1.2.4 Supervision and Patient Support
The Patients’ Charter for TB Care states that patients are the active recipients
of health care services. They have the right to seek information, care, privacy,
dignity, food supplements and other type of incentives. On the other hand, patients
have the responsibility to share their complete information with the health care
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providers, following the treatment, sharing in community health and exchanging the
experiences gained during the treatment with others in a community.
Ideally, anti-TB drugs should be administered under the direct supervision of
DOT staff to ensure that the patient takes right anti-TB drugs in right doses at right
intervals. However, to ensure completion of the treatment, the strategy to manage a
TB patient should be context-specific and patient-friendly. For example, if for
certain reasons, (e.g., psychologically handicap patients, prisoners, those unable to
come DOT center due to transportation problems, etc.) the patients are unable to
receive a daily therapy at the DOT clinic, efforts should be made to overcome the
barriers through community involvement. In this context, supporter of the treatment
may be the cured TB patients, close relatives, colleagues, religious leaders, general
medical practitioners, neighbors, community pharmacists and traditional healers.
However, the NTP staff is responsible for training and monitoring the non-medical
treatment supporters (World Health Organization, 2009).
1.2 Analysis of Treatment Outcome
WHO has set various benchmarks to evaluate the performance of NTP in order
to take appropriate and timely actions to control the burden of the disease. Among
these, WHO uses analysis of TB treatment outcome as an important yardstick.
In most parts of the world, standard categories are used to report the outcome
of TB treatment (World Health Organization, 2009). However, based on some
logical grounds, some European countries have modified the WHO outcome criteria
(Antoine, French, Jones, and Watson, 2007; Ditah et al., 2008). Nevertheless,
whatever outcome criteria is used, it allows the NTP mangers to identify specific
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problem which if addressed properly could improve the success rate of TB treatment.
For example, a higher proportion of the patients in default outcome category indicate
that the health care managers must adopt appropriate strategies to ensure the
patients’ adherence to TB treatment.
1.3 Health-Related Quality of Life Assessment
WHO defines ‘health’ as a state of complete physical, mental and social well-
being, and not merely the absence of disease or infirmity (World Health
Organization, 2003b). Although there are many types of equipment and instruments
to measure clinical and bio-physiological parameters of health, researchers and
clinicians have now realized that these only measure intermediate outcomes which
might not reflect the patients’ understanding of their own well-being. Nowadays, it is
known that an individual’s perception of his/her physical, mental and social well-
being could be measured in terms of health-related quality of life (HRQoL) (Spilker,
1996).
According to a recent systematic review and meta-analysis, numerous studies
have reported altered physical and mental health on the part of TB patients (Bauer,
Leavens, and Schwartzman, 2012). These studies have used a variety of instruments
to gauge the HRQoL of TB patients. In general, a valid and reliable HRQoL
measurement instrument is important to guarantee the accuracy, precision and
generalizability of the results. Whilst more research is required to develop a valid
disease-specific tool for TB patients, monitoring even their HRQoL through a
generic questionnaire like the Short-Form 36 version 2 (SF-36v2) could help health
care professionals to target the specific mental and physical health components
which are adversely affected by the disease or treatment. Likewise, this measurement
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could be used to predict how certain physiological, psychosocial, sociological,
economic and spiritual factors influence a patient’s well-being (Rajeswari,
Muniyandi, Balasubramanian, and Narayanan, 2005). Moreover, it would also allow
health care professionals to identify the patients who, due to disease, are at a higher
risk of altered HRQoL. Stratifying such patients is of critical importance in countries
where, either due to limited resources or higher TB incidence, a highly
individualized approach cannot be applied.
1.4 Cost of Tuberculosis Treatment
The intricacy and cost of TB treatment have risen in the recent years. The
emergence of MDR-TB, longer duration of TB treatment in HIV seropositive
patients, higher treatment failure rates in difficult-to-reach patients (i.e., drug
abusers, immigrants, etc.) and increasing demands of DOT programs contribute to
higher costs of TB treatment (Eliud, Bjarne, and Odd, 2005; Wurtz & White, 1999).
This has, therefore, put an extra pressure on health care budgets. According to one
estimate, approximately 70–80 % of TB cases are within the most productive age
group (15–54 years of age), and thereby the resultant economic loss to a society is
very high (Othman, Ibrahim, and Raja’a, 2012; World Health Organization, 2012).
Numerous studies have reported that patients and their families have to bear
direct and indirect costs of TB (Aspler et al., 2008; Rajeswari, Balasubramanian,
Muniyandi, Geetharamani, Thresa, and Venkatesan, 1999; Sinanovic, Floyd, Dudley,
Azevedo, Grant, and Maher, 2003). In many countries, TB patients seek initial
assistance from traditional healers or private health care sector either because of lack
of disease-related knowledge or preference of private health care sector due to the
perception that, compared with public providers, private providers are convenient,
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concerned and competent. Loss of earning due to illness and/or earlier mortality due
to TB are usually greater than direct cost of TB treatment (World Health
Organization, 2000).
On top of the economic costs, TB causes social and psychological costs. TB
patients may be rejected by the friends and family, or may be abstained from their
jobs. Such discrimination may result in depression, anxiety and diminished HRQoL
(World Health Organization, 2000).
The Global Plan to Stop TB 2011-2015 sets out the funding needed for the
implementation of TB care and control in low- and middle-income countries.
According to a recent report by WHO, an estimated amount of United States Dollars
(USD) 8 billion (in 2012 dollars) will be required, in 2015, for the diagnosis and
treatment of various forms of TB (World Health Organization, 2012). Malaysia has
already adopted the WHO Stop TB Strategy, and is working on a National Strategic
Plan for TB control 2011 to 2015. Consequently, Malaysian government has
allocated a total of USD 15 million (in 2012 dollars) for the free provision of TB
care through the network of public health care facilities. In Malaysia, the budget of
NTP is funded from the domestic sources without any contribution from the Global
Fund (United Nations, 2011; World Health Organization, 2012).
1.5 Problem Statement
The current NTP of Malaysia is functioning in line with the recent guidelines
of WHO, though have not been fully integrated in many parts of Peninsular Malaysia
(United Nations, 2011). In 2007, Malaysia surpassed the 70 % target in terms of
detection of new smear positive cases. However, over the past years, there was
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observed a decreasing pattern in TB treatment success rates (Nik, Mohd, Wan,
Sharina, and Nik, 2011; United Nations, 2011). A recent global TB report
documented that, over the last decade, TB cure rate was below 80 % in Malaysia
(World Health Organization, 2012). The failure to achieve the given target was
partially due to a higher proportion of patients lost follow-up and the weakness in
data management (United Nations, 2011). Another reason might be the pressure
exerted on the health care system due to an increasing number of cases over the past
years (United Nations, 2011; World Health Organization, 2012). With all of these
findings, it appears that there is still a room for improvement especially in terms of
making efforts to decrease the absolute number of annual TB cases, and to achieve a
better treatment success rate (Iyawoo, 2004).
At present, much of the attention within TB management is spent on
microbiological cure, and its impact on HRQoL is either undervalued or seldom
considered (Marra, Marra, Cox, Palepu, and Fitzgerald, 2004). Even, the most recent
guidelines on the management of TB are silent on this critical aspect (World Health
Organization, 2009). Existing literature shows that TB has substantial and
encompassing impact on the HRQoL of the infected patients. Stigma associated with
TB is a known factor which might affect patients’ mental well-being and life roles in
a community. Likewise, many patients have reported anxiety and depression even
after the completion of their TB treatment (Chamla, 2004; Guo, Marra, Marra,
Moadebi, Elwood, and FitzGerald, 2008).
The Patients’ Charter for TB Care allows the patients to evaluate the program’s
performance (World Health Organization, 2006b). From the patients’ perspective,
one of the major performance indicators might be the NTP’s capability to address the
18
physical and mental well-being of the patients. Therefore, the assessment of HRQoL
of TB patients, as an additional indicator of performance, will add value to the NTP.
Besides the worth of knowing prevalence and incidence rates for weighing the
burden of TB and highlighting the gravity of the epidemic, these pointers may fail to
explain the trends in the societal and economic burden of the disease (Ogden, 2000).
Therefore, it is crucial not only to highlight the importance of increasing TB
incidence rates, but also to address the structural and economic barriers which may
be acting together to fuel the epidemics (Aspler et al., 2008; Floyd, Blanc,
Raviglione, and Lee, 2002; McIntyre, Thiede, Dahlgren, and Whitehead, 2006).
The economic impact of TB is often measured in terms of direct and indirect
costs to the public health care services. These include the costs of medication,
employees and other health care facilities (World Health Organization, 2000).
Assessing the utilization of health care resources at governmental level is always
important in terms of provision of long-term planning in a highly dynamic health
economy (Wurtz & White, 1999). Furthermore, cost estimates are increasingly
required by insurance companies, government payers and others groups which are
alert to the allotment of limited research and treatment dollars.
In order to fully understand the impacts of TB on the well-being of the
members of society, there is a need to take into account the costs tolerated by the
patients, their families and communities. Nevertheless, these are occasionally
overlooked in favor of reducing the expenses of governmental agencies such as
departments of health (World Health Organization, 2000). In these circumstances,
too little investment occurs, and it may be allocated in a way which does not
minimize the burden of the disease. Moreover, this strategy does not enable the
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clinicians and NTP managers to make efficient health care choices (World Health
Organization, 2000).
1.6 Rationale of the Study
To justify the design and conduct of this study, the logical basis of each study
objective is given separately.
1.6.1 Analysis of Treatment Outcome
Assessment of treatment outcome of newly diagnosed smear positive PTB
patients is used as a major pointer to gauge the effectiveness of NTP. It enables the
NTP managers and staff to identify the problems, and take adequate and timely
actions to improve the overall performance of the program (Diel & Niemann, 2003;
Helbling, Medinger, Altpeter, Raeber, Beeli, and Zellweger, 2002; World Health
Organization, 2009).
WHO has recommended that countrywide cohort analysis of TB treatment
outcome should be performed every year. Furthermore, it is strongly recommended
that new smear positive PTB patients and previously treated patients (i.e., relapses,
defaulters and treatment failures) should be analyzed as separate cohorts because of
their different characteristics and probable results. WHO further recommends that
the treatment outcome should be monitored at peripheral, district, state and national
levels. Indeed, this strategy could identify the states or units which are performing
well, and thus would enable the NTP staff to replicate the successful practices
elsewhere (World Health Organization, 2009).
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According to a recent report by WHO, TB treatment success rate for new
smear positive PTB patients in Malaysia is still below the global success target of 85
% (World Health Organization, 2012). This report also highlights that the outcome
category death is one of the major reasons for non-attainment of the given target for
the treatment success. To date, a few studies from different states of Malaysia have
reported the treatment outcome of TB patients with a very high heterogeneity in the
results (Abdullah, Sulaiman, Ahmed, Muttalif, and Qais, 2011; Ismail & Bulgiba,
2013; Nik et al., 2011). Moreover, none of these studies have separately reported the
treatment outcome of new smear positive PTB patients. Indeed, this is the priority
group in terms of evaluating the performance of NTP.
Furthermore, most of the studies were conducted at the time when the patients
were notified and managed based on preceding TB treatment guidelines (World
Health Organization, 2003a). In addition, none of these studies have explored a
relationship between patient characteristics and mortality during TB treatment.
Similarly, the existing data are also lacking in terms of establishing a relationship
between patient characteristics and duration of TB treatment.
Based on the recommendations of WHO and the gaps in existing literature, one
could understand why it is urgent to conduct cohort analysis of new smear positive
PTB patients in the local settings.
1.6.2 Health-Related Quality of Life Assessment
With the advent of effective treatment strategies, the emphasis of TB
management has shifted from prevention of mortality to evasion of morbidity. To
attain this target, a client-oriented comprehensive NTP should address the social and
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emotional impact of the disease, and should adopt support strategies to enhance the
acceptance (Marra et al., 2004; Rajeswari et al., 2005).
The existing literature shows that, amongst TB patients in the Malaysian
population, there is a paucity of research with regard to their HRQoL. Likewise, only
two follow-up studies from Asia have reported changes in HRQoL with TB
treatment, although none used a widely acceptable HRQoL assessment tool (Dhingra
& Rajpal, 2005; Rajeswari et al., 2005). Moreover, there is nothing in the existing
literature regarding the assessment of HRQoL in the family caregivers of TB
patients.
One of the benefits of SF-36v2 norm-based scoring (NBS) is that it allows
general and simplified interpretation of the observations. In NBS, each scale is
scored using the same mean (50) and the same standard deviation (10 points) as
found in the United States (U.S.) general population. However, questions arise on
equivalence of the SF-36v2 standard (U.S. weights) scoring algorithms in the
Malaysian population. Therefore, it was deemed necessary to conduct a study aiming
to find out whether or not the Malaysia-specific scoring algorithms would give
results (scores) equivalent to those of the standard scoring algorithms. Equivalence
in results implies that instead of the country-specific approach, the U.S. standard SF-
36 summary scales (i.e., physical component summary and mental component
summary) and scoring algorithms could be used in the Malaysian population (Lam,
Tse, Gandek, and Fong, 2005; Ware et al., 1998).
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1.6.3 Cost Analysis
The basic underlying condition for an efficient allocation of the resources is to
know the financial cost of the disease. Without analyzing the costs, it is impossible
to contemplate or improve the efficiency of disease-control projects. In particular,
the ongoing reforms and decentralization processes in the health care systems of
developing countries require precise cost information (Su, Sanon, and Flessa, 2007).
For the most part, health care organizations use cost accounting for the estimation of
unit cost of their services, which helps them to plan a realistic budget and price for
the service (Sumeet, Kanchan, and Sonal, 2010).
Studies from developing countries have demonstrated that an average cost for
the treatment of a drug susceptible TB case ranged from USD 94.00 to USD 2058.00
(Aspler et al., 2008; Ayé, Wyss, Abdualimova, and Saidaliev, 2010; Elamin,
Ibrahim, Sulaiman, and Muttalif, 2008; Eliud et al., 2005; Okello, Floyd, Adatu,
Odeke, and Gargioni, 2003; Othman et al., 2012; Rajeswari et al., 1999; Sinanovic et
al., 2003). Similarly, studies from developed countries have shown a considerable
fluctuation in the average cost of TB treatment (Rubado, Choi, Becker, Winthrop,
and Schafer, 2008; Wurtz & White, 1999). The above mentioned data referring to the
cost of TB treatment is highly divergent because of differing health care systems,
perspectives (i.e., provider and patient), costs components, and methods of
calculation and data collection. This means that these pieces of data are neither
transferable nor any of implications arising from these studies can be applied to the
local settings (Diel, Rappenhöner, and Schaberg, 2004).
Wurtz & White (1999) have stressed the need to assess the resource utilization
pattern in TB due to following important reasons:
23
 To evaluate the relative contribution of outpatient and inpatient treatment
to the cost of TB diagnosis and treatment.
 To evaluate the relative contribution of different phases of treatment to
the cost of TB care.
 To provide long-term planning in changing health economy.
Notably, health system costs associated with tracing contacts of smear positive
PTB patients (index cases) are often neglected in most of the economic studies.
Indeed, data on costs and practicality of contact tracing can provide useful
information to the policymakers for taking appropriate measures to control the
slowly growing incidence rate and burden of the disease (Aspler et al., 2008; United
Nations, 2011). However, to date, no study from Malaysia has reported the cost and
practicality of contact tracing.
According to the economic findings, methodological concerns in comparing
various cost studies and scarcity of cost data on the management of newly diagnosed
smear positive PTB patients, one can understand why it is urgent to conduct this type
of economic evaluation in Malaysia. Currently, there is a gap in the Malaysian
literature concerning a comprehensive economic analysis of TB patients.
1.7 Research Contribution
A gradual increment in absolute number of TB cases in Malaysia is increasing
pressure on the NTP. Without any doubt, the achievement of 85 % treatment success
rate, provision of appropriate services to TB patients and maintaining the average
cost of TB treatment within allocated budget are the key challenges for the clinicians
and NTP managers.
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Within this context, it can be assumed that a study focusing on the above
mentioned issues is critical and timely. This study is expected to make following
unique research contributions that might be helpful for the policymakers in the local
and/or international settings:
 The study will describe socio-demographic, clinical and treatment
characteristics of smear positive PTB patients, and their treatment
outcome over a 1-year period. Moreover, this study will also underline
the risk factors for poor treatment outcome.
 This study will also describe the practices of the clinicians in relation to
the recent guidelines on the treatment of TB. Moreover, this study will
provide the policymakers with the empirical data required to decide
whether the standard treatment outcome criteria should be used or it
needs to be modified, as some of the European countries did, for a more
objective evaluation of the performance of NTP.
 This study will provide the evidence that whether the SF-36v2 standard
(U.S. weights) scoring algorithms and the U.S. standard summary scales
can be used in the Malaysian population.
 The findings of the study will highlight the impact of TB treatment on
the HRQoL of patients. Evidences of poor HRQoL among TB patients
will suggest that current practices of Malaysia’s NTP are unable to
address the psychological and social well-being of the patients. Indeed,
this baseline data will enable the NTP managers to decide the assessment
of HRQoL in TB patients, as an added parameter, to evaluate and
improve the NTP’s performance.
